World's Best Scientists 2026 revealed!

D-Index & Metrics

Immunology

D-Index
72
Citations
30029
World Ranking
2172
National Ranking
194

Overview

Adam Finn is affiliated with the University of Bristol in the United Kingdom. Their primary research field is Medicine, with a significant focus on Infectious Diseases, Epidemiology, and Pulmonary and Respiratory Medicine. Their work also extends into Health and Microbiology subfields.

The scientist has contributed extensively to topics related to SARS-CoV-2 and COVID-19 research, COVID-19 clinical research studies, and pneumonia and respiratory infections. Other key areas include respiratory viral infections research, bacterial infections and vaccines, vaccine coverage and hesitancy, and COVID-19 epidemiological studies.

Frequent coauthors collaborating with Adam Finn include:

  • León Danon
  • Catherine Hyams
  • Rajeka Lazarus
  • Nick Maskell
  • Saul N. Faust

The scientist has published articles in a range of venues, notably:

  • bioRxiv (Cold Spring Harbor Laboratory)
  • SSRN Electronic Journal
  • The Lancet
  • Vaccine
  • BMJ Open

Selected recent papers authored or coauthored by Adam Finn include:

  • Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK (2020, The Lancet)
  • Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial (2020, The Lancet)
  • Correlates of protection against symptomatic and asymptomatic SARS-CoV-2 infection (2021, Nature Medicine)
  • Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials (2021, The Lancet)
  • Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 variant of concern 202012/01 (B.1.1.7): an exploratory analysis of a randomised controlled trial (2021, The Lancet)

Adam Finn has contributed to several book publications, including works published by the Swiss School of Archaeology in Greece and Emerald Publishing Limited. Notable titles include "The COVID-19 vaccine communication handbook: A practical guide for improving vaccine communication and fighting misinformation" (2021) and "Measurement in Marketing" (2022).

Best Publications

  • Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK.

    M Voysey;Clemens Sac.;S A Madhi;L Y Weckx

  • Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial

    P M Folegatti;K J Ewer;P K Aley;B Angus

  • Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials.

    M Voysey;S A Costa Clemens;S A Madhi;L Y Weckx

  • Chemokine receptors and their role in inflammation and infectious diseases

    Craig Murdoch;Adam Finn

  • Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial

    Pedro M Folegatti;Katie J Ewer;Parvinder K Aley;Brian Angus

  • Valganciclovir for Symptomatic Congenital Cytomegalovirus Disease

    D. W. Kimberlin;P. M. Jester;P. J. Sánchez;A. Ahmed

  • Clinical spectrum of X-linked hyper-IgM syndrome

    Jacov Levy;Teresa Espanol-Boren;Carolin Thomas;Alain Fischer

  • Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 variant of concern 202012/01 (B.1.1.7): an exploratory analysis of a randomised controlled trial.

    Katherine R W Emary;Tanya Golubchik;Parvinder K Aley;Cristina V Ariani

  • Interleukin-17A Mediates Acquired Immunity to Pneumococcal Colonization

    Ying-Jie Lu;Jane Gross;Debby Bogaert;Adam Finn

  • Aspirin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial

    P W Horby;M Campbell;E Spata;Emberson

  • Safety and immunogenicity of heterologous versus homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine (Com-COV): a single-blind, randomised, non-inferiority trial.

    Xinxue Liu;Robert H Shaw;Arabella S V Stuart;Melanie Greenland

  • Interleukin-8 release and neutrophil degranulation after pediatric cardiopulmonary bypass.

    Adam Finn;Suren Naik;Nigel Klein;Roland J. Levinsky

  • Immunogenicity and Tolerability of Recombinant Serogroup B Meningococcal Vaccine Administered With or Without Routine Infant Vaccinations According to Different Immunization Schedules: A Randomized Controlled Trial

    Nicoletta Gossger;Matthew D. Snape;Ly-Mee Yu;Adam Finn

  • Immunogenicity, safety, and reactogenicity of heterologous COVID-19 primary vaccination incorporating mRNA, viral-vector, and protein-adjuvant vaccines in the UK (Com-COV2): a single-blind, randomised, phase 2, non-inferiority trial

    Unknown

  • Cxc chemokine receptor expression on human endothelial cells.

    Craig Murdoch;Peter N Monk;Adam Finn

  • Chronic Recurrent Multifocal Osteomyelitis (CRMO): advancing the diagnosis

    Marion Roderick;Ripal Shah;Valerie Rogers;Adam Finn;Adam Finn

  • Effect of a quadrivalent meningococcal ACWY glycoconjugate or a serogroup B meningococcal vaccine on meningococcal carriage: an observer-blind, phase 3 randomised clinical trial

    Robert C Read;David Baxter;David R Chadwick;Saul N Faust;Saul N Faust

  • Co-infections, secondary infections, and antimicrobial use in patients hospitalised with COVID-19 during the first pandemic wave from the ISARIC WHO CCP-UK study: a multicentre, prospective cohort study.

    Clark D Russell;Cameron J Fairfield;Thomas M Drake;Lance Turtle

  • Safety and immunogenicity of AS03B adjuvanted split virion versus non-adjuvanted whole virion H1N1 influenza vaccine in UK children aged 6 months-12 years: open label, randomised, parallel group, multicentre study

    Claire S Waddington;W T Walker;C Oeser;A Reiner

  • Reactogenicity and immunogenicity after a late second dose or a third dose of ChAdOx1 nCoV-19 in the UK: a substudy of two randomised controlled trials (COV001 and COV002).

    Amy Flaxman;Natalie G Marchevsky;Daniel Jenkin;Jeremy Aboagye

  • Single Dose Administration, And The Influence Of The Timing Of The Booster Dose On Immunogenicity and Efficacy Of ChAdOx1 nCoV-19 (AZD1222) Vaccine (preprint)

    Voysey, Merryn, Costa Clemens, Sue Ann, Madhi, Shabir A.;Weckx, Lily Yin, Folegatti, Pedro M.;Parvinder K. Aley;Angus, Brian John, Baillie, Vicky, Barnabas, Shaun L.

  • Valganciclovir for Symptomatic Congenital Cytomegalovirus Disease

    David W. Kimberlin;Penelope M. Jester;Pablo J. Sánchez;Amina Ahmed

Frequent Co-Authors

Andrew J. Pollard
Andrew J. Pollard University of Oxford
Paul T. Heath
Paul T. Heath St George's, University of London
Saul N. Faust
Saul N. Faust University Hospital Southampton NHS Foundation Trust
Matthew D. Snape
Matthew D. Snape University of Oxford
Shamez N. Ladhani
Shamez N. Ladhani UK Health Security Agency
Nigel Curtis
Nigel Curtis Royal Children's Hospital
Ray Borrow
Ray Borrow Manchester Royal Infirmary
Robert S. Heyderman
Robert S. Heyderman University College London
Caroline L. Trotter
Caroline L. Trotter University of Cambridge
Susanna Esposito
Susanna Esposito University of Parma

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

For those interested in Immunology, understanding related healthcare degrees can open up diverse career pathways. Many professionals transition into roles that combine immunology knowledge with clinical skills, such as nursing and specialized practitioner roles. Accelerated programs like the 12-month accelerated nursing programs offer a fast-track option for students looking to enter the nursing field quickly while leveraging their scientific background.

For entry-level clinical roles, options such as the easiest LPN programs to get into provide accessible pathways to begin hands-on patient care, a valuable experience for immunology graduates exploring healthcare.

Advancing further, the easiest nurse practitioner degree programs enable students to gain autonomy in clinical decision-making. Specializations like psychiatric mental health can be pursued through top programs such as the top pmhnp programs, which emphasize strong clinical placements—key for building practical skills.

Exploring these educational paths complements a foundation in Immunology, broadening both knowledge and career opportunities in the ever-evolving healthcare industry.

Best Scientists Citing Adam Finn

Trending Scientists

Recently Published Articles